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Abstract 
Endothelin-1 (ET-1), a 2 1 amino acid vasoconstrictor peptide synthesized by vascular endothelial cells, exerts powerful actions on the 
underlying smooth muscle cells. The receptor and signal transduction mechanisms for ET-1 have been well characterized in rat aortic A 10 
vascular smooth muscle cells (AIOVSMC). This investigation has characterized the internalization and metabolism of [J25I]ET-I by 
A1 0VSMC. A 1 0VSMC internalized [125I]ET-1 rapidly in a receptor-mediated manner. However, inhibition of the binding/internalization 
had no effect on the metabolism of [~25I]ET-I by these cells. Thus, the presence of excess unlabeled ET-1 in the incubation, treatment of 
the cells with ET receptor antagonists, and homologous ligand-induced down-regulation f the ET-I receptor all inhibited binding and 
internalization of [ ~25I]ET-1 by A IOVSMC, but not its metabolism. Furthermore, addition of excess unlabeled ET-I to the incubations 
containing cells pretreated with the homologous ligand (receptor down-regulated cells) also failed to inhibit the metabolism of [ J25I]ET-1. 
Essentially similar characteristics of [J25I]ET-I binding and metabolism were exhibited by primary cultures of smooth muscle cells 
derived from rat thoracic aorta. Such ability of the vascular smooth muscle cells to degrade ET-1, which is produced constitutively by the 
endothelial cells, presents a novel mechanism in the regulation of its local and circulating concentration. 
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I. Introduction 
Endothelin-I (ET-I), a powerful vasoconstrictor pep- 
tide, is synthesized by the vascular endothelial cells [1]. In 
addition to its contractile action, ET-1 also exerts mito- 
genic effects on vascular smooth muscle cells (VSMC) in 
concert with a number of growth factors [2-5]. These 
properties of ET-I and its elevated circulating levels in 
disorders uch as hypertension [6], atherosclerosis [7], dia- 
betes [8], and myocardial infarction [9] implicate its possi- 
ble involvement in the pathogenesis of cardiovascular 
complications. 
The physiologic circulating levels of ET-1 are in the 
low picomolar range. Several mechanical and chemical 
stimuli have been shown to enhance the synthesis of ET-1 
by endothelial cells. Thus, pathophysiologic conditions 
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such as endothelial injury, hypoxia/ischemia, stress, 
trauma, and exposure of the endothelial cells to substances 
such as thrombin, interleukins, and endotoxins have been 
shown to increase ET-1 synthesis (reviewed in Refs. [10- 
13]). In these situations metabolism of ET-1 by the VSMC 
may be crucial in regulating its concentration at the local 
sites as well as in the circulation. A rat aortic smooth 
muscle cell line, A10VSMC, has been widely used to 
investigate the biology and pathobiology of vascular 
smooth muscle. The ET-! receptor on VSMC has been 
shown to be predominantly of the ET A type (ET-l-selec- 
tive) [14,15]; this receptor has been cloned and sequenced 
[16], and the mechanisms of receptor binding and ET-I 
actions in VSMC have been characterized[2-5,14,17]. The
metabolism of many peptide agonists requires receptor- 
mediated internalization prior to their degradation by the 
intracellular enzymes [18-20], and a similar mechanism 
has been suggested for ET-1 degradation [21]. However, 
the present investigation demonstrates that the inhibition of 
binding/intemalization f ET-1 in vascular smooth muscle 
cells does not affect its metabolism by these cells. 
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2. Mater ia l s  and  methods  
2.1. Culture of VSMC 
repeated. Cells were digested with 0.5 M NaOH, and 
radioactivity in cell digests and combined acid fractions 
was determined. 
The clonal smooth muscle cell line derived from rat 
thoracic aorta (A10VSMC) was obtained from American 
Type Culture Collection, Rockville, MD in 15th passage. 
Cells were maintained in DMEM containing 10% fetal calf 
serum and penicillin/streptomycin at 37°C in a humidified 
atmosphere of 95% air /5% CO 2, and were used between 
passages 18 and 32. Each experiment was repeated 2-3 
times using cells in different passages. Cells were allowed 
to reach confluence before experiments were performed. 
Smooth muscle cells from rat thoracic aorta were pre- 
pared as described by Smith and Brock [22]. Cells were 
grown in DMEM containing 10% fetal calf serum and 
penicillin/streptomycin ~tt 37°C in a humidified atmo- 
sphere of 95% air /5% CO 2, and were used between 
passages 4 and 6 at confl~aency. 
2.2. Determination ofsurface-bound and internalized ET-1 
Cells were washed fount imes with Hank's balanced salt 
solution containing 0 1% bovine serum albumin 
(HBSS/BSA)  and placed in this medium containing 10 
pM []25I]ET-1 _ 25 nM unlabeled ET-1. Following incu- 
bation at 37°C for times indicated in the figure legends, 
cells were washed four times with ice-cold HBSS/BSA 
and placed in 1 ml ice-cold 50 mM glycine buffer (pH 
3.0), containing 100 mM NaCI [23]. After 10 min on ice, 
the medium was aspirated and the acid treatment was 
2.3. Metabolism of [125I]ET-1 
Cells were washed three times with HBSS/BSA and 
were placed in 1 ml of this medium containing 10 pM 
[leSI]ET-I _ 25 nM unlabeled ET-1. After incubation at 
37°C for the times indicated in the figure legends, the 
medium was aspirated and saved for the determination of 
[~25I]ET-1 metabolites. Cells were washed four times with 
ice-cold HBSS/BSA and digested with 0.5 M NaOH, then 
radioactivity in the NaOH-digests was determined. The 
metabolites of [ 125 I]ET-1 in the medium were separated by 
sequential precipitation with trichloroacetic acid (TCA, 
final concentration of 10%) and silver nitrate (AgNO 3, 
final concentration, 1.7%). Radioactivity in the resultant 
pellets and the supernatants was determined. This is a 
quick and reliable method for determining the metabolism 
of endothelin [23], as the entire procedure requires only 
10-15 min, and several samples can be processed simulta- 
neously. The validity of the TCA precipitation method was 
confirmed by HPLC identification of [I25I]ET-1 metabo- 
lites in the supernatants from TCA-and AgNO3-soluble 
fractions (Fig. 1). 
To determine [~25I]ET-1 metabolites in the cells, in 
some experiments cells were treated with TCA after wash- 
ing with HBSS/BSA and the radioactivity in the TCA- 
soluble and TCA-insoluble material was determined. Addi- 
tionally, cell-associated radioactive material was extracted 
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Fig. 1. HPLC tracing of [l~5I]Eq?-I and its metabolites from A10VSMC incubations. After a 3-h incubation ofAIOVSMC with 10 pM [12~I]ET-1 at 37°C, 
the medium was loaded on the HPLC column and the metabolites separated asdescribed inSection 2. Control, whole medium; TCA-soluble, supematant 
after TCA precipitation; AgNO:rsoluble, supernatant af er TCA and AgNO 3 precipitation. Peak 7 is [12~I]ET-1. For clarity, the tracings are separated by
100 C.P.M. 
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with 10% acetic acid and was subjected to HPLC separa- 
tion for determination f [~25I]ET-1 and its metabolites. 
Nonspecific degradation of [125 I]ET- 1 was assessed by 
determination f radioactivity in the TCA supernatant from 
incubations in the absence of cells. 
2.4. High pressure liquid chromatography 
HPLC separation of [ ~25I]ET- 1 and its metabolites was 
carried out on a Waters HPLC apparatus equipped with a 
Waters data module and an ODS column (4.6 mm × 250 
mm, Beckman) [23]. A linear gradient of 0.1% trifluoro- 
acetic acid (TFA) in water and 0.1% TFA in 70% aceto- 
nitrile was developed over 70-min period at a flow rate of 
1 ml/min. Medium from the incubations of cell culture 
was applied directly to the column and the radioactivity 
was determined by an in-line detector. 
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Fig. 2. Time course of the metabolism of ['25I]ET-I. Cells were incu- 
bated with 10 pM [125I]ET-I at 37°C for indicated times, washed and 
digested with NaOH. The medium was treated with TCA and the 
radioactivity in the cell-digests, TCA precipitate and TCA supernatants 
was determined. Values (C.P.M./plate_ S.D.) represent averages of trip- 
licate determinations from two separate xperiments. 
2.5. Materials 
Phosphoramidon, dansylcadaverine, bacitracin and 
thiorphan (Sigma Chemicals, St. Louis, MO), Dubelcco's 
modified Eagle's medium (GIBCO, Gaithersburg, MD), 
fetal calf serum (FCS) (HyClone, Logan, UT), endothelin- 1 
(Peninsula Laboratories, Belmont, CA), and [125I]Tyr 13-en- 
dothelin-1 (2200 Ci/mmol, New England Nuclear, Boston, 
MA) were purchased. Endothelin receptor antagonists 
RO462005, FR139317, and BQ123 were kindly provided 
by Dr. J. Ruth Wu-Wong, Abbott Laboratories, Abbott 
Park, IL. All other chemicals and reagents were of the 
highest purity available. 
3. Results 
3.1. Metabolism of [125I]ET-1 by AIOVSMC 
At least six distinct peaks of [125I]JET-1 metabolites 
were observed upon their separation by HPLC (Fig. 1); 
peak 7 was identified as intact ['25I]ET-1. It is likely that 
the metabolism of ET-1 can result in the generation of 
fragments that do not contain Tyr ~3. Since the determina- 
tion of ET-1 metabolites was based upon the presence of 
[tzsI]Tyr13, nonradioactive metabolites could not be identi- 
fied. However, such limitation does not undermine the 
validity of the outcome of this investigation. Fig. 1 demon- 
strates that TCA specifically precipitated [ I2SI]ET-1 leav- 
ing all of the radiolabeled metabolites in the supernatant, 
whereas AgNO 3 precipitated all but the metabolites ap- 
pearing as peaks 1 (22 min) and 2 (25 min) on HPLC. In 
another experiment, he cell-associated radioactivity was 
found to be predominantly TCA-precipitable and, hence, 
represented [125I]ET- 1. For example, radioactivity in the 
NaOH-digest of the cells following a 3-h incubation at 
37°C was 14312 ___ 1213 cpm, and that in the TCA-pre- 
cipitate in another set of plates from the same experiment 
was 13149 + 2100 cpm. Furthermore, cell-associated ra- 
dioactive material extracted from incubations of A IOVSMC 
with [I25I]ET-1 eluted as a single peak with authentic 
[J25I]ET-1 on HPLC. 
Since TCA precipitation is a very reliable and quick 
procedure for the analysis of the metabolism of [125I]ET-1 
[23], and as all of the metabolites of [125I]ET-I were found 
to be TCA-soluble (Fig. 1), during the determination f the 
time course of [~25I]ET-1 binding/metabolism, the culture 
supernatants were treated with TCA, and radioactivity in 
the cell-digests as well as the TCA precipitates and the 
supernatants was measured. As illustrated in Fig. 2, there 
was a time-dependent decrease in the TCA-precipitable 
radioactivity, with a corresponding increase in the radioac- 
tivity associated with cells and TCA-supernatant. For times 
up to 1 hour of incubation, TCA-soluble radioactivity was 
nearly equal to that in the cell-digests, after which 
[125I]ET-1 metabolites (TCA-soluble fraction) exceeded 
cell-associated radioactivity (Fig. 2). 
3.2. Time course of the binding, internalization, and 
metabolism of ET-1 
Fig. 3 illustrates the time course of the binding/inter- 
nalization of ET- 1 at physiologic temperature. [125 I]ET- 1 
was rapidly internalized following its binding to the recep- 
tor. For up to 15 min, the cell-surface-associated (acid-re- 
leasable) [125I]ET-1 equaled the internalized (acid-re- 
sistant) ligand; thereafter, the acid-resistant ligand ex- 
ceeded the acid-releasable ligand at all time points during 
the incubation. Acid-releasable [t25I]ET-1 peaked between 
30 min and 1 hour of incubation and declined thereafter. A 
comparison between the binding of [125I]ET-1 at 37°C and 
4°C indicated that the total cell-associated radioactivity at 
37°C was approximately four times higher than that at 4°C. 
This was found to be due to internalization of the peptide 
at 37°C, a process inhibited at 4°C. Thus, at the higher 
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Table I 
Effect of temperature on internalization/metabolism of [ t_~ 5 I]ET- 1 by A 10VSMC 
293 
4°C 37°C 
- Unlabeled ET-1 + Unlabeled ET-I - Unlabeled ET-I + Unlabeled ET-I 
Acid-wash 1095 + 86 87 -I- 7 495 -I- 56 184 + 34 
Cell-digest 498 + 37 186 -I- 4 5847 ± 46 236 -I- 28 
TCA-supernatant 2323 + 68 2026 -I- 79 14111 ± 348 13789 ± 403 
Cells were washed and placed ill HBSS/BSA containing 10 pM [I-~51]ET-I (35,000 ___ 2900 C.P.M.)-t-25 nM unlabeled ET-I and incubated at 4°C or 
37°C for 3 h. Cells were then washed and treated with acidic medium as described in Section 2. Medium was treated with TCA and radioactivity in the 
cell-digests (internalized ligand), acid-washes (cell-surface-associated ligand), and TCA supernatants (ET-l-metabolites) was determined. Results are 
expressed as C.P.M. in various fiactions and represent average values of triplicate determinations + S.D. from three separate xperiments. Radioactivity in 
TCA-supernatants in the absence of cells (nonspecific degradation) was found to be 2143 + 49 at 4°C and 2387 + 125 at 37°C. 
temperature, only 8% of the total cell-associated ligand 
was acid-releasable, as against 69% at the lower tempera- 
ture (Table 1). 
3.3. Effect of dansylcadaLerine, bacitracin, and phospho- 
ram±don on the binding, internalization, and metabolism of 
[leSl]ET-1 
As iigand internalization has been shown to be the 
primary step required for the degradation of various pep- 
tides by intracellular enzymes [18-20], inhibitors of pep- 
tide internalization were tested to determine metabolism of 
ET-I by AIOVSMC. Dansylcadaverine is an inhibitor of 
transglutaminase, an enzyme implicated in the internaliza- 
tion of receptor-ligand complexes [24-27]. However, at a 
dansylcadaverine concentration as high as 500 /zM, only 
22% of the cell-associated radioactivity was acid-releasa- 
ble (control, 6%) (Fig. 3, 7'able 2). Furthermore, no signif- 
icant difference in the acid-resistant radioactivity and the 
metabolism of ET-I was observed between control and 
dansylcadaverine-treated oells (Fig. 3, Table 2). 
Another inhibitor of transglutaminase, bacitracin [24- 
27], was also tested to ascertain the process of [125I]ET-1 
internalization i A10VSMC. Bacitracin had no effect on 
the acid-releasable fraction in A10VSMC and, interest- 
ingly, stimulated internalization of [125I]ET-1 (Table 2). 
Bacitracin, which is also an inhibitor of aminopeptidase 
activity [28,29], partially inhibited the metabolism of 
[12SI]ET-l. From HPLC separation of the metabolites, 
bacitracin was found to inhibit the formation of [12SI]ET-1 
metabolites appearing in AgNO3-soluble fraction (HPLC 
peaks 1 and 2) (Fig. 4). Phosphoramidon, an inhibitor of 
neutral metalloproteases [29,30], also stimulated the inter- 
nalization of [12SI]ET-1, but to a greater extent han baci- 
tracin, and completely inhibited the metabolism of 
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Fig. 3. Time course of the binding/internalization f [125I]ET-I by 
AIOVSMC - effect of dansylcadaverine. Cells were washed and incu- 
bated in HBSS/BSA containing 10 pM [125I]ET-1 +500 /xM dansylca- 
daverine for the indicated times. Cells were then washed, treated with the 
acidic medium and digested with NaOH. Radioactivity in the acid-washes 
and the cell-digests was determined. Each point (C.P.M./plate+S.D.) 
represents an average of triplicate determinations from two separate 
experiments. Hollow and filled symbols represent control and dansylca- 
daverine-treated cells respectively; O O, acid-resistant radioactivity; [] 
II, acid-releasable radioactivity. Other details are described in Section 2. 
Table 2 
Effect of inhibitors on [125I]ET-I internalization and its metabolism by A10VSMC 
Condition Cell surface-associated Internalized ligand Metabolites 
(acid-wash) (cell-digest) (TCA-supernatant) 
No addition 534 -f- 40 8860 + 320 17002 + 1121 
+ ET-I 365 + 11 456 + 30 19372 ± 1895 
+ Bacitracin 649 + 33 14892 ± 510 9164 + 188 
+ Phosphoramidon 915 _+ 41 20543 ± 1179 751 4-_ 34 
+ Dansylcadaverine 2707 + 144 8766 + 1166 16625 + 567 
Cells were washed and incubated in the presence of 10 pM [1251]ET-I (41 000 _+ 4100 C.P.M.) for 3 h at 37°C in a medium containing 25 nM unlabeled 
ET-I, I mM bacitracin, 1 /xM phosphoramidon r 500 /xM monodansylcadaverine. Following incubation, the cells were treated with acidic medium 
(glycine buffer, pH 3.0) and digested with NaOH. The medium was treated with 10% TCA. Radioactivity in the cell-digests, acid-washes, and TCA 
supernatants was determined. Values (C.P.M. in various fractions) represent an average of triplicate determinations _ S.D. from three experiments. For 
other details, see Section 2. 
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Fig. 4. HPLC tracing of [125I]ET-1 and its metabolites from AIOVSMC incubations in the presence of bacitracin and phosphoramidon. Medium from the 
incubations of A10VSMC with 10 pM [125I]ET-1 at 37°C for 3 h was used for separation of the metabolites by HPLC. For other details, see legends for 
Fig. 1, Table 2, and Section 2. For clarity, the tracings are separated by 100 C.P.M. 
[125I]ET-1 (Table 2, Fig. 4). A similar effect of thiorphan 
(100/zM), as that of phosphoramidon, on [125I]ET-I bind- 
ing/internalization and metabolism (results not shown), 
suggests that the enzyme(s) involved in the metabolism of 
ET-1 is neutral endopeptidase. The increase in the concen- 
tration of internalized [t2SI]ET-1 in the presence of these 
inhibitors may have occurred as a result of its decreased 
metabolism. Other protease inhibitors, e.g., leupeptin (10 
/zg/ml), aprotinin (10/xg/ml), pepstatin (10/xg/ml) and 
phenylmethylsulfonylfluoride (1 mM) had no effect on 
binding/internalization and metabolism of [125I]ET-1 by 
A10VSMC (results not shown). 
3.4. Effect of excess unlabeled ET-1, receptor down-regu- 
lation, and receptor antagonists on [1251]ET-1 binding /
metabolism by AIOVSMC 
If the metabolism of ET-1 is an intracellular process, 
then excess unlabeled ET-1 should inhibit binding/inter- 
nalization as well as the metabolism of trace amounts of 
Table 3 
125 Effect of homologous ligand-induced receptor down-regulation  the metabolism of [ I]ET-I by AIOVSMC 
Control Down-regulated 
- Unlabeled ET-1 + Unlabeled ET-1 - Unlabeled ET-1 + Unlabeled ET-I 
Experiment at 37°C 
Cell-digest 5549 ___ 228 227 5- 21 769 5:63 270 5- 61 
Metabolites 17498 5:521 18584 5:442 18273 ± 1189 18220 5:487 
(3108 + 73) (2775 ___ 118) 
Experiment at 4°C 
Cell-digest 1387 + 34 161 ___ 29 147 5:21 132 _+ 23 
Metabolites 3127 + 57 3157 + 204 3171 5- 170 3136 5:156 
(3281 5: 216) (3232 5: 480) 
Cells were washed and incubated in the presence or absence of 50 nM unlabeled ET-1 for 3 h. Cells were then washed extensively and placed in 
HBSS/BSA containing 10 pM [125I]ET-1 (38000 + 3450 C.P.M.) + 50 nM unlabeled ET-1 and incubated at 4°C or 37°C for 3 h. The supernatant was 
treated with 10% TCA and after centrifugation, radioactivity in the supernatant (ET-I metabolites) was determined. Cells were washed 4 times with 
ice-cold HBSS/BSA, digested with NaOH and the radioactivity in the cell-digests (internalized + cell-surface-associated ligand) was determined. To 
determine nonspecific degradation of [125I]ET-1, solution containing radiolabeled ligand + unlabeled ET-1 was incubated in the absence of cells and the 
radioactivity in the TCA supernatant was determined (numbers in parentheses). Values (C.P.M. in various fractions) represent an average of triplicate 
determinations ___ S.D. from three experiments. For other details, see Section 2. 
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Table 4 
Effect of endothelin receptor antagonists onthe metabolism of [125I]ET-I by AIOVSMC 
295 
Internalized ligand Cell surface-associated Metabolites 
(cell-digest) (acid-wash) (TCA-supernatant) 
Control 5948 + 143 513 _ 57 15984 __ 1421 
+ ET-1 1323 + 26 176 + 45 17818 + 559 
FR139317 :280 + 18 157 + 34 18486 5:570 
BQI23 437 5:17 197 ___ 89 18407 + 486 
RO462005 406 + 10 134 5:41 18833 5:3155 
Cells were washed and incubated in the presence of 10 pM [125I]ET-1 (47000 + 5200 C.P.M.) for 3 h at 37°C in a medium containing carrier (control), 25 
nM unlabeled ET-I, and ET receptor antagonists RO462005 (10 ARM), FR139317 (10 /xM) and BQI23 (1 /xM). Following incubation, the medium was 
aspirated and treated with 10% TCA. Cells were treated with acid medium as described inSection 2, and radioactivity n the cell digests, acid washes and 
TCA supernatants was determined. Values (C.P.M. in various fractions) represent an average oftriplicate determinations + S.D. from three xperiments. 
For other details, ee Section 2. 
[~25I]ET-1 by A10VSMC. Consistent with the former sug- 
gestion, at physiologic temperature, xcess unlabeled ET-1 
(25 nM) reduced by 96% the acid-resistant (internalized) 
fraction and inhibited by 63% the acid-releasable (cell 
surface-associated) fraction of [125I]ET-1 (Table 1). How- 
ever, as determined by the TCA precipitation method 
(Tables 1-3), as well as by the separation of the metabo- 
lites by HPLC (Fig. 5), no inhibition of [125I]ET-I (10 pM) 
metabolism was observed in the presence of excess unla- 
beled ET-1 (25-50 nM). A time course of this process up 
to 6 h also indicated that excess unlabeled ET-1 did not 
affect [125I]ET-1 metabolism at any time during incubation 
(results not shown). 
To confirm further that the receptor-ligand interaction 
and ligand internalization are not required for the 
metabolism of ET-1 by AIOVSMC, the ET-I receptor was 
down-regulated by incubation with the homologous ligand 
for 3 h. This procedure completely inhibited the specific 
binding of ET-I to A10VSMC (Table 3, experiment at 
4°C). When the down-regulated cells were incubated at 
37°C for 3 h in the presence of [125I]ET-1 + unlabeled 
ET-1, only 10% recovery of specific binding (association) 
of [ 125I]ET_ 1 occurred (Table 3). However, this procedure 
caused no inhibition of [125I]ET-I metabolism, even in the 
presence of excess unlabeled ET-1 in incubations with 
receptor down-regulated cells (Table 3). Since excess unla- 
beled ET-1 inhibited binding/internalization but not 
metabolism of [~25I]ET-1, the possibility that these cells 
may secrete ET-metabolizing enzyme(s) in the medium 
was explored. However, no metabolism of [125I]ET-1 oc- 
curred upon its incubation with conditioned medium from 
A10VSMC (results not shown). Taken together these re- 
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Fig. 5. Effect of excess unlabeled ET-I on [125I]ET-I metabolism byAIOVSMC-HPLC tracing. Cells were incubated with 10 pM [125I]ET-1 + 25 nM 
unlabeled ET- 1 for 3 h. The medium from these incubations was used for separation f metabolites byHPLC. See legend for Fig. 1 and Section 2for other 
details. For clarity, the tracings are separated by200 C.P.M. 
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Table 5 
Metabolism of [125I]ET-1 by aortic smooth muscle cells 
Cell-associated ET-I metabolites 
ET- 1 (TCA supernatant) 
Control (10 pM [1251]ET-1) 2460_+296 6348+ 161 
+ Unlabeled ET-1 (50 nM) 206+32 6561 + 153 
Down-regulated + ET-I (50 nM) 190-+44 6456-+ 115 
BQ 123 (1 #M) 421 _+30 6681 _+ 110 
RO462005 (10/.LM) 175_+21 6398+314 
Bacitracin (1 raM) 2964_+ 121 3255 _+ 186 
Phosphoramidon (1 /xM) 3294+ 199 973+74 
Thiorphan (100/xM) 3381 _+ 391 810 _+ 98 
Aortic smooth muscle cells were grown to confluency in passages 4-6. 
Cells were washed and incubated in the presence of l0 pM [L~SI]ET-1 
(32000_+770 C.P.M.) for 3 h at 37°C in the medium containing various 
agents at indicated concentrations. The assay conditions were essentially 
as described in Tables 2-4. Results are expressed as mean C.P.M. _+ S.D. 
from triplicate determinations of a representative of 3 experiments. 
suits suggest that [~25I]ET-1 is metabolized on the surface 
of A 10VSMC. 
Finally, the effects of three ET receptor antagonists 
(FR139317, BQ123, and RO462005) on the 
binding/metabolism of [125I]ET-1 by A10VSMC were 
examined. Receptors for ET-1 on A10VSMC have been 
shown to be predominantly the ET A type (selective for 
ET-1) [14,15]. BQ123 and FR 139317 are selective ET A 
antagonists with an ECso in nanomolar ange, whereas 
RO462005 is a nonselective antagonist [31-34]. These 
antagonists were found to abrogate completely the specific 
association of [~25I]ET-1 with the cells and its internaliza- 
tion, but did not inhibit its metabolism (Table 4). 
3.5. Metabolism of [lesI]ET-1 by aortic smooth muscle 
cells 
To ascertain the physiologic relevance of ET-1 
metabolism by the immortal rat aortic cell line A10VSMC, 
some of the key experiments were performed using pri- 
mary cultures of rat aortic smooth muscle cells. Essentially 
same results were obtained as illustrated in Table 5. While 
addition of excess unlabeled ET- 1 to the incubation medium 
(before and after homologous ligand-induced receptor 
down-regulation) and ET receptor antagonists inhibited 
binding/internalization f trace amounts of [125I]ET-1, 
these treatments did not exert any effect on its metabolism. 
Bacitracin partially inhibited [125I]ET-1 metabolism while 
phosphoramidon a d thiorphan completely inhibited this 
process. These inhibitors, however, enhanced binding of 
[125I]ET-1 to the cells. 
4. Discussion 
Binding of endothelin-1 to its receptor and the attendant 
signal transduction processes have been characterized in
aortic VSMC as well as the aortic smooth muscle cell line 
A10VSMC [2-5,14-17]. In this investigation, the mecha- 
nisms of ET-1 uptake and its metabolism by A10VSMC 
have been characterized. The binding of [125I]ET-1 to 
A10VSMC was followed by its rapid internalization as 
determined by the resistance of the cell-associated ligand 
to the acid treatment. Furthermore, the presence of excess 
unlabeled ET-I or ET receptor antagonists in the incuba- 
tions abrogated both cell-associated as well as acid-releasa- 
ble radioactivity (Tables 1 and 2, and 4), implicating that 
[125I]ET_1 internalization is a receptor-mediated process. 
Receptor-mediated endocytosis i a principal mechanism 
for the internalization and degradation of various exoge- 
nous substances; internalized receptor is either degraded, 
recycled to the cell surface, or extruded from the cell, and 
the translocated ligand is degraded by intracellular en- 
zymes [18-20]. The enzyme transglutaminase has been 
shown to be involved in the internalization of receptor- 
ligand complexes, and inhibition of this enzyme by dansyl- 
cadaverine attenuates the internalization of receptor-ligand 
complexes [24-27]. However, at a concentration of 500 
/zM the acid-resistant radioactivity was not significantly 
different in dansylcadaverine-treated A10VSMC as com- 
pared with the untreated cells (Fig. 3, Table 2). At this 
concentration (500/zM), dansylcadaverine has been shown 
to inhibit internalization of peptides, including ET-1, in 
other cell systems [25-27,35]. Furthermore, another trans- 
glutaminase inhibitor bacitracin also did not inhibit the 
internalization of ET-1 (Table 2). Thus, receptor-mediated 
internalization of ET-1 in A10VSMC appears to follow 
other mechanisms than activation of transglutaminase. 
The metabolites of [125I]ET-1 derived from A10VSMC 
incubations were separated into six major peaks by HPLC. 
The chemical composition of these radiolabeled intermedi- 
ates could not be determined ue to their extremely low 
quantities generated in the experiments of this investiga- 
tion. However, the hydrolytic products of [ ~25 I]ET- 1 from 
incubations with purified neutral endopeptidase 24.11 were 
observed to separate into six distinct peaks by HPLC [36]. 
In the HPLC system used in this investigation, authentic 
iodotyrosine lutes at about 18 min, suggesting that all of 
the [125I]ET-1 metabolites (peaks 1 through 6) represent 
metabolites of dipeptide size or greater. Although 
[125 I]ET-hydrolyzing enzyme(s) both from hepatocytes [23] 
and the kidney [37] were found to dehalogenate [~2SI]ET-1, 
with an HPLC elution time for [125I] of less than 5 min, no 
dehalogenation f [125I]ET-1 was observed in A10VSMC 
incubations. 
Previously, a strong inhibitory effect of bacitracin on 
the metabolism of [125I]ET-1 by hepatocytes was demon- 
strated [23]. Bacitracin caused only partial inhibition of 
[~25I]ET-1 metabolism in A10VSMC, which was specifi- 
cally apparent in AgNO3-soluble metabolite species (peaks 
1 and 2, see Fig. 4). However, the metabolism of [ 125I]ET-1 
was completely abrogated by the neutral metalloprotease 
inhibitors phosphoramidon a d thiorphan [38] (and present 
investigation). Phosphoramidon has also been shown to 
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inhibit ET-1 metabolism by purified neutral endopeptidase 
24.11 [36] and in the kidney preparations [37,39]. These 
observations suggest involvement of distinct peptidases in 
the degradation of ET-I by VSMC and hepatocytes. In
human umbilical endothelial cells, ET-1 binding could be 
detected when ET-1 synthesis was inhibited by incubation 
with phosphoramidon [40]. Interestingly, phosphoramidon 
inhibited degradation of ET receptors and thus caused an 
increase in ET-1 binding to Swiss 3T3 fibroblasts [41]. In 
view of the latter finding, increase in cell-associated 
[125I]ET-1 in incubations containing phosphoramidon may 
have occurred as a result of the inhibition of (a) receptor 
degradation and/or (b) ET- 1 metabolism. 
Recently, a lysosomal deamidase of VSMC with acidic 
pH optimum, which inactivates ET-1 by cleaving Trp21, 
has been reported in the., soluble fractions of vascular 
smooth muscle cells frona rat lungs [21]; the authors 
concluded that like other peptide hormones ET-1 degrada- 
tion could be regulated by receptor-mediated endocytosis. 
However, the results of this investigation indicate that 
ET-1 internalization i  VSMC is not necessary for its 
degradation as implicated by the metabolism of [ 12SI]ET-1 
in the presence of exces,; unlabeled ET-1. Furthermore, 
excess unlabeled ET-I did not inhibit the metabolism of 
[125I]ET-1 by VSMC in which the ET-1 receptor was 
completely down-regulated (Tables 3 and 5). An explana- 
tion for the inability of excess unlabeled ET-1 to inhibit 
the degradation of trace anaounts of [125I]ET-1 may be that 
the K m of the neutral endopeptidase for ET-I metabolism 
is 2.3 /zM [36], whereas the maximal concentration of 
ET-1 used in this investigation was 50 nM. Therefore, 
since the K d value for ET-1 binding is in the pM 
range[14,42], atnM concentration (e.g., 25-50 nM), unla- 
beled ET-1 will prevent he binding of pM concentrations 
of [125I]ET-1. However, at these concentrations of unla- 
beled ET-1, [125I]ET-1 metabolism will be unaffected ue 
to the high K m of the enzyme. 
The receptor on vascular smooth muscle cell is pre- 
dominantly ET A subtype (selective for ET-1), and this 
receptor has been cloned and sequenced [16]. However, 
recent evidence indicated the presence of ET B receptor 
(nonselective for ET isopeptides) also on these cells [re- 
viewed in [43,44]]. It has been demonstrated that ET a 
receptor-mediated internalization of ET-I is primarily re- 
sponsible for its clearance from the circulation [47]. There- 
fore, both ETA-specific as well as mixed ETA/ET a recep- 
tor antagonists were used to ascertain the involvement of 
these receptors on ET-I internalization and metabolism. 
Both of these receptor antagonists failed to inhibit 
metabolism of ET-1 by VSMC although they completely 
inhibited its binding/internalization, further supporting the 
suggestion that metabolisra of ET-I is not an intracellular 
process (Tables 4 and 5). 
Incubation of vascular endothelial cells with human 
bronchial smooth muscle cells [45], and A10VSMC and 
fibroblasts [46] or with conditioned medium from the latter 
cell types resulted in decreased release of ET-I. It was 
suggested that a factor released by the vascular smooth 
muscle cells and fibroblasts has inhibitory effect on ET-1 
synthesis in endothelial cells. Cade et al. [45] also ob- 
served decrease in ET-I content in the medium from 
endothelial cells when it was added to the smooth muscle 
cell culture, suggesting that smooth muscle cells possibly 
metabolize ET-I. The results of the present investigation 
extend the observation made by Cade et al. [45] and 
provide the first evidence that at the local site of synthesis 
in the vasculature, clearance of ET-1 does not necessitate 
receptor-mediated internalization. In fact ET-1 is catabo- 
lized very efficiently on the surface of VSMC in the 
absence of a functional receptor. 
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